These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 19238016)

  • 21. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.
    Mancikova V; Smida M
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
    Kochenderfer JN; Rosenberg SA
    Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
    Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.
    Lee DW; Barrett DM; Mackall C; Orentas R; Grupp SA
    Clin Cancer Res; 2012 May; 18(10):2780-90. PubMed ID: 22589486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
    Terakura S; Yamamoto TN; Gardner RA; Turtle CJ; Jensen MC; Riddell SR
    Blood; 2012 Jan; 119(1):72-82. PubMed ID: 22031866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of advanced leukemia in mice with mRNA engineered T cells.
    Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
    Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
    Davila ML; Bouhassira DC; Park JH; Curran KJ; Smith EL; Pegram HJ; Brentjens R
    Int J Hematol; 2014 Apr; 99(4):361-71. PubMed ID: 24311149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
    Brentjens RJ; Santos E; Nikhamin Y; Yeh R; Matsushita M; La Perle K; Quintás-Cardama A; Larson SM; Sadelain M
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5426-35. PubMed ID: 17855649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
    Cruz CR; Micklethwaite KP; Savoldo B; Ramos CA; Lam S; Ku S; Diouf O; Liu E; Barrett AJ; Ito S; Shpall EJ; Krance RA; Kamble RT; Carrum G; Hosing CM; Gee AP; Mei Z; Grilley BJ; Heslop HE; Rooney CM; Brenner MK; Bollard CM; Dotti G
    Blood; 2013 Oct; 122(17):2965-73. PubMed ID: 24030379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies.
    Luo Y; Qie Y; Gadd ME; Manna A; Rivera-Valentin R; To T; Li S; Yassine F; Murthy HS; Dronca R; Kharfan-Dabaja MA; Qin H
    Cancer Immunol Immunother; 2023 Dec; 72(12):4031-4047. PubMed ID: 37814001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.
    Faitschuk E; Hombach AA; Frenzel LP; Wendtner CM; Abken H
    Blood; 2016 Sep; 128(13):1711-22. PubMed ID: 27535994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.
    Pegram HJ; Purdon TJ; van Leeuwen DG; Curran KJ; Giralt SA; Barker JN; Brentjens RJ
    Leukemia; 2015 Feb; 29(2):415-22. PubMed ID: 25005243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
    Nagle K; Tafuto B; Palladino Kim L; Parrott JS
    Med Oncol; 2018 Sep; 35(11):144. PubMed ID: 30206753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
    Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
    Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.
    Davila ML; Kloss CC; Gunset G; Sadelain M
    PLoS One; 2013; 8(4):e61338. PubMed ID: 23585892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.